Nuclear localization of NRF2 in stroma of HER2 positive and triple-negative breast cancer

Pathol Res Pract. 2023 Aug:248:154662. doi: 10.1016/j.prp.2023.154662. Epub 2023 Jul 5.

Abstract

Breast cancer is one of the leading causes of cancer-related mortality in women. During tumor growth, periods of hypoxia are followed by reoxygenation due to neovascularisation leading to disturbed redox homeostasis. ROS (Reactive Oxygen Species) produced under hypoxia activate HIF1α. ROS can also activate the major antioxidant transcription factor NRF2, but also cause damage to biomolecules. Lipids are susceptible to peroxidation, as evidenced by the formation of reactive aldehydes, among which, HNE (4-hydroxynonenal) is the most studied one. Knowing that HIF1α (Hypoxia Inducing Factor 1α) is associated with breast cancer malignancy, we aimed to investigate its correlation with HNE and NRF2 (Nuclear factor erythroid 2-related factor 2). Our results show that HIF1α is activated in breast cancer, indicating an increase in ROS but not followed by HNE production. On the other hand, NRF2 was increased in all types of breast cancer suggesting that oxidative stress is present in these pathologies, but also supporting HIF1α. Interestingly, NRF2 was activated in HER2 positive and TNBC, indicating the role of stromal NRF2 in breast cancer malignancy.

Keywords: 4-hydroxynonenal; Breast cancer; HIF1α; NRF2.

MeSH terms

  • Female
  • Humans
  • Hypoxia
  • NF-E2-Related Factor 2 / metabolism
  • Oxidative Stress
  • Reactive Oxygen Species
  • Triple Negative Breast Neoplasms* / pathology

Substances

  • Reactive Oxygen Species
  • NF-E2-Related Factor 2